$55.99
8.55% yesterday
Nasdaq, Dec 03, 10:10 pm CET
Why the stock moved Why the stock moved Beta
ISIN
CH0334081137
Symbol
CRSP

CRISPR Therapeutics AG Stock price

$55.99
-5.98 9.65% 1M
+17.95 47.19% 6M
+16.63 42.25% YTD
+4.75 9.27% 1Y
+3.88 7.45% 3Y
-84.47 60.14% 5Y
+41.90 297.37% 10Y
+41.90 297.37% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+4.41 8.55%
ISIN
CH0334081137
Symbol
CRSP
Industry

New AI Insights on CRISPR Therapeutics AG Insights AI Insights on CRISPR Therapeutics AG

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$5.3b
Enterprise Value
$3.4b
Net debt
positive
Cash
$1.9b
Shares outstanding
93.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
139.2 | 165.8
EV/Sales
89.2 | 101.2
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
86.2%
Return on Equity
-19.0%
ROCE
-22.5%
ROIC
-153.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$38.3m | $29.7m
EBITDA
$-459.5m | $-572.6m
EBIT
$-478.1m | $-609.9m
Net Income
$-488.3m | $-592.9m
Free Cash Flow
$-328.1m
Growth (TTM | estimate)
Revenue
-81.1% | -20.5%
EBITDA
-46.8% | -28.0%
EBIT
-43.8% | -30.7%
Net Income
-103.8% | -61.9%
Free Cash Flow
-71.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,198.5% | -1,931.1%
EBIT
-1,247.2%
Net
-1,273.7% | -1,999.4%
Free Cash Flow
-855.9%
More
EPS
$-5.3
FCF per Share
$-3.5
Short interest
27.3%
Employees
393
Rev per Employee
$90.0k
Show more

Is CRISPR Therapeutics AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

CRISPR Therapeutics AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a CRISPR Therapeutics AG forecast:

22x Buy
61%
13x Hold
36%
1x Sell
3%

Analyst Opinions

36 Analysts have issued a CRISPR Therapeutics AG forecast:

Buy
61%
Hold
36%
Sell
3%

Financial data from CRISPR Therapeutics AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
38 38
81% 81%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 233 233
16% 16%
608%
- Research and Development Expense 283 283
15% 15%
739%
-459 -459
47% 47%
-1,198%
- Depreciation and Amortization 19 19
4% 4%
49%
EBIT (Operating Income) EBIT -478 -478
44% 44%
-1,247%
Net Profit -488 -488
104% 104%
-1,274%

In millions USD.

Don't miss a Thing! We will send you all news about CRISPR Therapeutics AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CRISPR Therapeutics AG Stock News

Positive
The Motley Fool
4 days ago
Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.
Positive
The Motley Fool
4 days ago
It may be the spawn of a company that faded into irrelevancy, but GE Vernova is thriving as a standalone outfit. Most investors may not appreciate just how long it takes CRISPR Therapeutics to complete a dosing regimen and start collecting revenue.
Positive
The Motley Fool
13 days ago
Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.
More CRISPR Therapeutics AG News

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Samarth Kulkarni
Employees 393
Founded 2013
Website crisprtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today